CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 150 enrolled
Drug / intervention
VARIVAX™biological
Likely dose
VARIVAX™ 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03843632
NCT03843632Phase 3Completed
CompareCT.gov

An Open-Label, Multicenter, Single-arm Study to Evaluate the Immunogenicity of VARIVAX™ in Healthy Russian Individuals 12 Months of Age and Older

Merck Sharp & Dohme LLC·interventional·Posted Feb 18, 2019·Updated Apr 6, 2021

In Brief

A Phase 3 clinical trial evaluating VARIVAX™ for Varicella. Completed, enrolled 150 participants across 5 sites.

Detailed Summary

The purpose of this study was to evaluate the immunogenicity and safety of VARIVAX™ vaccine in healthy Russian children, adolescents, and adults. No formal hypothesis was tested.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaricella
CountriesRussia
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedFeb 18, 2019
Enrollment StartMar 1, 2019
Primary CompletionJun 19, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.4 years ago

Interventions

VARIVAX™biological

VARIVAX™ administered by SC injection as 0.5 mL Varicella Virus Vaccine Live in sterile suspension on Day 1 (all participants) and Day 43 (adult and adolescent participants).